Floatz logo

Amivantamab-Vmjw

Colorectal Neoplasm

Janssen Research & Development, LLCmonoclonal_antibodyPhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

117 Active assets in the Colorectal Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BB

View all 50 →

Same molecule, other indications

Amivantamab-Vmjw is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
54 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →